Literature DB >> 35303428

TFPI is a colonic crypt receptor for TcdB from hypervirulent clade 2 C. difficile.

Jianhua Luo1, Qi Yang1, Xiaofeng Zhang2, Yuanyuan Zhang3, Li Wan2, Xiechao Zhan2, Yao Zhou1, Liuqing He1, Danyang Li1, Dazhi Jin4, Ying Zhen2, Jing Huang2, Yanyan Li5, Liang Tao6.   

Abstract

The emergence of hypervirulent clade 2 Clostridioides difficile is associated with severe symptoms and accounts for >20% of global infections. TcdB is a dominant virulence factor of C. difficile, and clade 2 strains exclusively express two TcdB variants (TcdB2 and TcdB4) that use unknown receptors distinct from the classic TcdB. Here, we performed CRISPR/Cas9 screens for TcdB4 and identified tissue factor pathway inhibitor (TFPI) as its receptor. Using cryo-EM, we determined a complex structure of the full-length TcdB4 with TFPI, defining a common receptor-binding region for TcdB. Residue variations within this region divide major TcdB variants into 2 classes: one recognizes Frizzled (FZD), and the other recognizes TFPI. TFPI is highly expressed in the intestinal glands, and recombinant TFPI protects the colonic epithelium from TcdB2/4. These findings establish TFPI as a colonic crypt receptor for TcdB from clade 2 C. difficile and reveal new mechanisms for CDI pathogenesis.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CDI pathogenesis; CRISPR/Cas9 screen; Clostridioides difficile; TcdB; clade 2 C. difficile; colonic crypt; cryo-EM structure; receptor; tissue factor pathway inhibitor

Mesh:

Substances:

Year:  2022        PMID: 35303428     DOI: 10.1016/j.cell.2022.02.010

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  7 in total

1.  Scientists struggle to probe COVID's origins amid sparse data from China.

Authors:  Amy Maxmen
Journal:  Nature       Date:  2022-03       Impact factor: 49.962

Review 2.  From signal transduction to protein toxins-a narrative review about milestones on the research route of C. difficile toxins.

Authors:  Klaus Aktories
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-10-07       Impact factor: 3.195

3.  Another surprise in receptor binding of C. difficile toxins.

Authors:  Klaus Aktories
Journal:  Innovation (Camb)       Date:  2022-05-18

4.  Paeniclostridium sordellii hemorrhagic toxin targets TMPRSS2 to induce colonic epithelial lesions.

Authors:  Xingxing Li; Liuqing He; Jianhua Luo; Yangling Zheng; Yao Zhou; Danyang Li; Yuanyuan Zhang; Zhenrui Pan; Yanyan Li; Liang Tao
Journal:  Nat Commun       Date:  2022-07-26       Impact factor: 17.694

Review 5.  Clostridium difficile Induced Inflammasome Activation and Coagulation Derangements.

Authors:  Marta Mattana; Riccardo Tomasello; Claudia Cammarata; Paola Di Carlo; Teresa Fasciana; Giulio Giordano; Alessandro Lucchesi; Sergio Siragusa; Mariasanta Napolitano
Journal:  Microorganisms       Date:  2022-08-10

6.  LDLR, LRP1, and Megalin redundantly participate in the uptake of Clostridium novyi alpha-toxin.

Authors:  Yao Zhou; Danyang Li; Diyin Li; Aizhong Chen; Liuqing He; Jianhua Luo; Liang Tao
Journal:  Commun Biol       Date:  2022-09-05

7.  Protocol for genome-wide CRISPR knockout screens of bacterial cytotoxins in HeLa cells.

Authors:  Qi Yang; Yao Zhou; Liuqing He; Yuanyuan Zhang; Liang Tao
Journal:  STAR Protoc       Date:  2022-07-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.